Iovance Biotherapeutics, Inc.

IOVA

Find Out if You Qualify for a Financial Reward by filling out the form below.

Iovance Biotherapeutics, Inc. Form












Class Action Lawsuit List does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

On December 27, 2023, Iovance announced that, on December 22, 2023, the U.S. Food and Drug Administration (“FDA”) had placed a clinical hold on the Company’s IOV-LUN-202 trial, which was investigating the Iovance’s lead product candidate for the treatment of metastatic non-small cell lung cancer. Iovance advised that the FDA’s decision to place the clinical hold was “in response to a recently reported Grade 5 (fatal) serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen.”

On this news, Iovance’s stock price fell 18.67% to close at $7.23 per share on December 27, 2023.

Active Cases

Ticker Symbol Company Name Join Deadline Join
APLT Applied Therapeutics, Inc. February 18, 2025 Join
BIOA BioAge Labs, Inc. March 10, 2025 Join
PCRX Pacira BioSciences, Inc. March 14, 2025 Join
NVO Novo Nordisk A/S March 25, 2025 Join
GO Grocery Outlet Holding Corp. March 31, 2025 Join
NEM Newmont Corporation April 01, 2025 Join
GSK GSK plc April 07, 2025 Join
NTLA Intellia Therapeutics, Inc. April 14, 2025 Join
MRK Merck & Co., Inc. April 14, 2025 Join